|
Volumn 119, Issue 4, 2002, Pages 247-258
|
Zafirlukast (Accolate®): A review of its pharmacological and clinical profile
|
Author keywords
Anti peptideleukotriene drug; Antiasthmatic; CysLT 1 receptor; Long term controller; Zafirlukast
|
Indexed keywords
LEUKOTRIENE;
LEUKOTRIENE C4;
LEUKOTRIENE D4;
LEUKOTRIENE E4;
ZAFIRLUKAST;
ANTIASTHMATIC AGENT;
CYSTEINYL LEUKOTRIENE RECEPTOR 2;
LEUKOTRIENE D4 RECEPTOR;
LEUKOTRIENE RECEPTOR;
LEUKOTRIENE RECEPTOR BLOCKING AGENT;
MEMBRANE PROTEIN;
TOLUENESULFONIC ACID DERIVATIVE;
ANIMAL CELL;
ANIMAL EXPERIMENT;
ANIMAL MODEL;
ANIMAL TISSUE;
ASTHMA;
BRONCHUS HYPERREACTIVITY;
CONTROLLED STUDY;
DOSE RESPONSE;
DRUG EFFICACY;
DRUG RECEPTOR BINDING;
DRUG STRUCTURE;
DYSPNEA;
EOSINOPHIL;
GUINEA PIG;
HYPERSENSITIVITY;
LUNG PARENCHYMA;
NONHUMAN;
PATHOPHYSIOLOGY;
REVIEW;
SHEEP;
TRACHEA;
ANIMAL;
BINDING COMPETITION;
BRONCHOSPASM;
CLINICAL TRIAL;
DRUG EFFECT;
HUMAN;
METABOLISM;
PHYSIOLOGY;
ANIMALS;
ANTI-ASTHMATIC AGENTS;
ASTHMA;
BINDING, COMPETITIVE;
BRONCHOCONSTRICTION;
CLINICAL TRIALS;
GUINEA PIGS;
HUMANS;
LEUKOTRIENE ANTAGONISTS;
LEUKOTRIENES;
MEMBRANE PROTEINS;
RECEPTORS, LEUKOTRIENE;
TOSYL COMPOUNDS;
|
EID: 0036235724
PISSN: 00155691
EISSN: None
Source Type: Journal
DOI: 10.1254/fpj.119.247 Document Type: Review |
Times cited : (1)
|
References (19)
|